Abstract

To overcome yearly efforts and costs for the production of seasonal influenza vaccines, new approaches for the induction of broadly protective and long-lasting immune responses have been developed in the past decade. To warrant safety and efficacy of the emerging crossreactive vaccine candidates, it is critical to understand the evolution of influenza viruses in response to these new immune pressures. Here we applied unique molecular identifiers in next generation sequencing to analyze the evolution of influenza quasispecies under in vivo antibody pressure targeting the hemagglutinin (HA) long alpha helix (LAH). Our vaccine targeting LAH of hemagglutinin elicited significant seroconversion and protection against homologous and heterologous influenza virus strains in mice. The vaccine not only significantly reduced lung viral titers, but also induced a well-known bottleneck effect by decreasing virus diversity. In contrast to the classical bottleneck effect, here we showed a significant increase in the frequency of viruses with amino acid sequences identical to that of vaccine targeting LAH domain. No escape mutant emerged after vaccination. These results not only support the potential of a universal influenza vaccine targeting the conserved LAH domains, but also clearly demonstrate that the well-established bottleneck effect on viral quasispecies evolution does not necessarily generate escape mutants.

Highlights

  • Influenza A viruses (IAVs) remain a major public health concern, causing severe respiratory tract infections, especially in young children, the elderly, and patients with chronic and multiple morbidities

  • These findings demonstrate that long alpha helix (LAH) is a promising candidate as a safe and potent universal influenza vaccine target

  • The LAH domain from pH1N1/09 has been incorporated into hepatitis B virus core protein (HBc) using recently developed tandem core technology [9]

Read more

Summary

Introduction

Influenza A viruses (IAVs) remain a major public health concern, causing severe respiratory tract infections, especially in young children, the elderly, and patients with chronic and multiple morbidities. IAV vaccine strategies rely on a protective antibody response against the hemagglutinin (HA) and neuraminidase (NA). Both of these surface glycoproteins are highly variable among IAVs circulating in humans and animals [3]. It is essential to improve current vaccines and to develop drift resistant strategies providing a broad and lasting protection. Such universal IAV vaccines are based on conserved domains of viral proteins. In contrast to the conserved influenza matrix protein and nucleoprotein epitopes, which provide only weak protection in human challenge studies [1], the conserved stalk portion of HA is a much more potent candidate for a universal vaccine [1,5,6]. The highly conserved long α-helix (LAH) of the stalk domain spanning amino acid (aa) 76–130 has been shown to induce broadly reactive and protective Ab responses [7,8,9]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.